Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IONS NASDAQ:JAZZ OTCMKTS:OPHLF NASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIONSIonis Pharmaceuticals$73.28-0.7%$74.98$34.78▼$86.74$12.11B0.372.06 million shs1.96 million shsJAZZJazz Pharmaceuticals$230.56-2.4%$216.77$105.00▼$243.32$14.48B0.32993,250 shs635,707 shsOPHLFOno Pharmaceutical$14.55$14.55$9.20▼$18.67$6.84B0.32121 shsN/ASRPTSarepta Therapeutics$15.31+2.1%$19.37$10.41▼$38.09$1.62B0.212.92 million shs2.27 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIONSIonis Pharmaceuticals+0.68%-1.74%-2.65%+3.69%+103.98%JAZZJazz Pharmaceuticals+2.85%-1.62%+3.66%+32.27%+113.73%OPHLFOno Pharmaceutical0.00%0.00%0.00%+3.93%+37.24%SRPTSarepta Therapeutics-0.73%-9.96%-21.59%-8.54%-60.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIONSIonis Pharmaceuticals$73.28-0.7%$74.98$34.78▼$86.74$12.11B0.372.06 million shs1.96 million shsJAZZJazz Pharmaceuticals$230.56-2.4%$216.77$105.00▼$243.32$14.48B0.32993,250 shs635,707 shsOPHLFOno Pharmaceutical$14.55$14.55$9.20▼$18.67$6.84B0.32121 shsN/ASRPTSarepta Therapeutics$15.31+2.1%$19.37$10.41▼$38.09$1.62B0.212.92 million shs2.27 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIONSIonis Pharmaceuticals+0.68%-1.74%-2.65%+3.69%+103.98%JAZZJazz Pharmaceuticals+2.85%-1.62%+3.66%+32.27%+113.73%OPHLFOno Pharmaceutical0.00%0.00%0.00%+3.93%+37.24%SRPTSarepta Therapeutics-0.73%-9.96%-21.59%-8.54%-60.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIONSIonis Pharmaceuticals 2.90Moderate Buy$100.9037.69% UpsideJAZZJazz Pharmaceuticals 2.84Moderate Buy$246.066.72% UpsideOPHLFOno Pharmaceutical 2.00HoldN/AN/ASRPTSarepta Therapeutics 2.07Hold$24.7761.81% UpsideCurrent Analyst Ratings BreakdownLatest IONS, JAZZ, OPHLF, and SRPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)6/10/2026JAZZJazz Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$281.00 ➝ $307.006/9/2026JAZZJazz Pharmaceuticals Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform6/9/2026JAZZJazz Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$256.005/27/2026IONSIonis Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$125.005/27/2026JAZZJazz Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$234.00 ➝ $253.005/26/2026JAZZJazz Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)5/26/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/22/2026JAZZJazz Pharmaceuticals Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$232.00 ➝ $301.005/21/2026JAZZJazz Pharmaceuticals Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Perform$229.005/21/2026JAZZJazz Pharmaceuticals Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIONSIonis Pharmaceuticals$1.06B11.44N/AN/A$3.02 per share24.26JAZZJazz Pharmaceuticals$4.44B3.26$16.33 per share14.12$71.07 per share3.24OPHLFOno Pharmaceutical$3.43B2.00$1.08 per share13.50$11.07 per share1.31SRPTSarepta Therapeutics$2.18B0.74N/AN/A$10.89 per share1.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIONSIonis Pharmaceuticals-$381.39M-$2.07N/AN/AN/A-30.91%-58.65%-10.07%8/5/2026 (Estimated)JAZZJazz Pharmaceuticals-$356.15M-$0.02N/A10.320.210.66%14.56%5.25%8/4/2026 (Estimated)OPHLFOno Pharmaceutical$463.46M$0.9914.7017.74N/A13.51%8.55%6.58%8/3/2026 (Estimated)SRPTSarepta Therapeutics-$713.41M-$0.96N/A5.890.16-2.94%7.56%2.94%8/5/2026 (Estimated)Latest IONS, JAZZ, OPHLF, and SRPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026SRPTSarepta Therapeutics$0.9760$3.16+$2.1840$2.88$474.16 million$730.80 million5/5/2026Q1 2026JAZZJazz Pharmaceuticals$4.67$6.34+$1.67$4.43$978.66 million$974.98 million4/29/2026Q1 2026IONSIonis Pharmaceuticals-$0.85-$0.56+$0.29-$0.56$195.57 million$246.09 million3/31/2026Q1 2026JAZZJazz PharmaceuticalsN/A$6.34N/A$4.43N/A$1.07 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIONSIonis PharmaceuticalsN/AN/AN/AN/AN/AJAZZJazz PharmaceuticalsN/AN/AN/AN/AN/AOPHLFOno PharmaceuticalN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIONSIonis Pharmaceuticals2.754.104.09JAZZJazz Pharmaceuticals0.952.041.85OPHLFOno Pharmaceutical0.103.022.56SRPTSarepta Therapeutics0.564.632.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIONSIonis Pharmaceuticals93.86%JAZZJazz Pharmaceuticals89.14%OPHLFOno PharmaceuticalN/ASRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipIONSIonis Pharmaceuticals1.81%JAZZJazz Pharmaceuticals4.30%OPHLFOno PharmaceuticalN/ASRPTSarepta Therapeutics6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIONSIonis Pharmaceuticals1,402165.26 million162.27 millionOptionableJAZZJazz Pharmaceuticals2,89062.82 million60.12 millionOptionableOPHLFOno Pharmaceutical4,287469.91 millionN/ANot OptionableSRPTSarepta Therapeutics1,372105.58 million98.29 millionOptionableIONS, JAZZ, OPHLF, and SRPT HeadlinesRecent News About These CompaniesING Groep NV Cuts Stock Holdings in Sarepta Therapeutics, Inc. $SRPTJune 10 at 5:28 AM | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Recommendation of "Hold" from BrokeragesJune 10 at 2:17 AM | americanbankingnews.comAll You Need to Know About Sarepta Therapeutics (SRPT) Rating Upgrade to BuyJune 8, 2026 | finance.yahoo.comIs Sarepta (SRPT) Using New Equity Plans To Quietly Redefine Its Post‑Profitability Playbook?June 8, 2026 | finance.yahoo.comSarepta Therapeutics, Inc. (SRPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comSRPT vs. ARGX: Which Stock Is the Better Value Option?June 8, 2026 | finance.yahoo.comAll You Need to Know About Sarepta Therapeutics (SRPT) Rating Upgrade to BuyJune 8, 2026 | zacks.comSRPT vs. ARGX: Which Stock Is the Better Value Option?June 8, 2026 | zacks.comBioGene Therapeutics Inc. Appoints Ty Howton to Board of DirectorsJune 8, 2026 | finance.yahoo.comSarepta Therapeutics, Inc. $SRPT Shares Sold by BNP Paribas Financial MarketsJune 7, 2026 | marketbeat.comImproving Profitability Supports Sarepta Therapeutics Inc. (SRPT) as One of the Most Shorted Small-Cap Stocks to BuyJune 5, 2026 | finance.yahoo.comImproving Profitability Supports Sarepta Therapeutics Inc. (SRPT) as One of the Most Shorted Small-Cap Stocks to BuyJune 5, 2026 | insidermonkey.comWhy Is Sarepta Therapeutics (SRPT) Down 19.9% Since Last Earnings Report?June 5, 2026 | finance.yahoo.comWhy Is Sarepta Therapeutics (SRPT) Down 19.9% Since Last Earnings Report?June 5, 2026 | zacks.comSarepta Shareholders Approve 2026 Equity and ESPP PlansJune 4, 2026 | tipranks.comSRPT Expands Into Huntington’s Disease With New First-in-Human TrialJune 4, 2026 | tipranks.comSarepta Therapeutics, Inc. (SRPT) Shareholder/Analyst Call TranscriptJune 4, 2026 | seekingalpha.comSarepta Therapeutics to Participate in Upcoming Investor ConferencesJune 1, 2026 | finance.yahoo.comSarepta Therapeutics to Participate in Upcoming Investor ConferencesJune 1, 2026 | businesswire.comIn Solid Cash Position, Sarepta Therapeutics Inc (SRPT) Outlines 2026 PrioritiesMay 27, 2026 | finance.yahoo.comAssessing Sarepta Therapeutics (SRPT) Valuation After Recent Share Price WeaknessMay 26, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesQuantum Stocks Just Got a Lifeline—Who Benefits Most?By Nathan Reiff | May 26, 2026Is Everspin Technologies the Next AI Edge Breakout?By Thomas Hughes | May 18, 2026As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants InBy Leo Miller | May 17, 2026These 3 CLO ETFs Target a Niche Corner of the Fixed-Income MarketBy Nathan Reiff | May 31, 2026As Small-Cap Outperformance Continues, These 2 ETFs Provide ExposureBy Jessica Mitacek | May 21, 2026IONS, JAZZ, OPHLF, and SRPT Company DescriptionsIonis Pharmaceuticals NASDAQ:IONS$73.28 -0.54 (-0.73%) Closing price 04:00 PM EasternExtended Trading$73.26 -0.02 (-0.02%) As of 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.Jazz Pharmaceuticals NASDAQ:JAZZ$230.56 -5.61 (-2.38%) Closing price 04:00 PM EasternExtended Trading$232.44 +1.88 (+0.82%) As of 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.Ono Pharmaceutical OTCMKTS:OPHLF$14.55 0.00 (0.00%) As of 06/11/2026Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.Sarepta Therapeutics NASDAQ:SRPT$15.31 +0.31 (+2.07%) Closing price 04:00 PM EasternExtended Trading$15.34 +0.03 (+0.19%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
